Epstein-Barr Virus, But Not Human Papillomavirus, Is Associated With Preinvasive and Invasive Ocular Surface Squamous Neoplasias in Zambian Patients.
Epstein–Barr virus
Zambia
human immunodeficiency virus
human papillomavirus
ocular surface squamous neoplasia
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
01
2022
accepted:
11
03
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
The etiopathogenesis of ocular surface squamous neoplasia (OSSN) is not fully understood. We assessed the frequency of oncogenic viruses in OSSN by immunohistochemistry (IHC) and polymerase chain reaction (PCR) for human papillomavirus (HPV), Epstein-Barr virus (EBV), Merkel cell polyomavirus (MCPyV), Kaposi sarcoma virus, and adenovirus. Cases from Zambia were prospectively enrolled using a cross-sectional study design between November 2017 and March 2020. Demographic and clinical data [age, sex, HIV status, antiretroviral therapy (ART) history, CD4 count, plasma viral load] and tumor biopsies were collected from 243 consenting patients. Tumor samples were bisected, and half was used for DNA isolation, while the other half was formalin fixed and paraffin embedded (FFPE) for histopathology analysis. The expressions of latent EBV nuclear antigen 1 (EBNA1), CDKN2A/p16INK4A (p16), and MCPyV large T-antigen (LT) were tested by IHC. Multiplex PCR was used to detect 16 HPV genotypes and four other DNA tumor viruses [Kaposi's sarcoma-associated herpesvirus (KSHV), EBV, MCPyV, and adenovirus]. Relationships between HIV status, viral DNA and protein expression, and tumor grades were determined by statistical analysis. OSSN tumors from patients were 29.6% preinvasive and 70.4% invasive. Patients presented with unilateral tumors that were 70.4% late stage (T3/T4). OSSN patients were HIV positive (72.8%). IHC on 243 FFPE biopsies resulted in the detection of EBNA1 (EBV), p16 high-risk HPV (HR-HPV), and MCPyV LT expression in 89.0%, 4.9%, and 0.0%, respectively. EBNA1 was expressed in all grades of preinvasive [cornea-conjunctiva intraepithelial neoplasia (CIN)1, 100%; CIN2, 85.7%; CIN3, 95.8%; and carcinoma Our findings of EBV DNA and EBNA1 protein in all the grades of preinvasive and especially invasive OSSN are consistent with a potential causal role for EBV in OSSN. A role of HPV in OSSN was not clearly established in this study.
Sections du résumé
Background
UNASSIGNED
The etiopathogenesis of ocular surface squamous neoplasia (OSSN) is not fully understood. We assessed the frequency of oncogenic viruses in OSSN by immunohistochemistry (IHC) and polymerase chain reaction (PCR) for human papillomavirus (HPV), Epstein-Barr virus (EBV), Merkel cell polyomavirus (MCPyV), Kaposi sarcoma virus, and adenovirus. Cases from Zambia were prospectively enrolled using a cross-sectional study design between November 2017 and March 2020.
Methods
UNASSIGNED
Demographic and clinical data [age, sex, HIV status, antiretroviral therapy (ART) history, CD4 count, plasma viral load] and tumor biopsies were collected from 243 consenting patients. Tumor samples were bisected, and half was used for DNA isolation, while the other half was formalin fixed and paraffin embedded (FFPE) for histopathology analysis. The expressions of latent EBV nuclear antigen 1 (EBNA1), CDKN2A/p16INK4A (p16), and MCPyV large T-antigen (LT) were tested by IHC. Multiplex PCR was used to detect 16 HPV genotypes and four other DNA tumor viruses [Kaposi's sarcoma-associated herpesvirus (KSHV), EBV, MCPyV, and adenovirus]. Relationships between HIV status, viral DNA and protein expression, and tumor grades were determined by statistical analysis.
Results
UNASSIGNED
OSSN tumors from patients were 29.6% preinvasive and 70.4% invasive. Patients presented with unilateral tumors that were 70.4% late stage (T3/T4). OSSN patients were HIV positive (72.8%). IHC on 243 FFPE biopsies resulted in the detection of EBNA1 (EBV), p16 high-risk HPV (HR-HPV), and MCPyV LT expression in 89.0%, 4.9%, and 0.0%, respectively. EBNA1 was expressed in all grades of preinvasive [cornea-conjunctiva intraepithelial neoplasia (CIN)1, 100%; CIN2, 85.7%; CIN3, 95.8%; and carcinoma
Conclusions
UNASSIGNED
Our findings of EBV DNA and EBNA1 protein in all the grades of preinvasive and especially invasive OSSN are consistent with a potential causal role for EBV in OSSN. A role of HPV in OSSN was not clearly established in this study.
Identifiants
pubmed: 35494029
doi: 10.3389/fonc.2022.864066
pmc: PMC9047892
doi:
Types de publication
Journal Article
Langues
eng
Pagination
864066Informations de copyright
Copyright © 2022 Julius, Siyumbwa, Moonga, Maate, Kaile, Haynatski, Minhas, Snow, Peterson, Gihozo, Streeter, Kaur, Evans, Gonzalez, Samwel, Kang, West, Wood and Angeletti.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Acta Med Iran. 2011;49(11):707-14
pubmed: 22131239
Lancet. 1996 May 25;347(9013):1450-1
pubmed: 8676629
Am J Dermatopathol. 2018 Jul;40(7):486-490
pubmed: 29533279
Saudi J Ophthalmol. 2016 Apr-Jun;30(2):113-6
pubmed: 27330387
Scientifica (Cairo). 2012;2012:438204
pubmed: 24278697
Infect Agent Cancer. 2010 Mar 26;5:6
pubmed: 20346104
Ophthalmology. 2015 Nov;122(11):2210-5
pubmed: 26337001
Medicine (Baltimore). 2019 Jan;98(2):e13944
pubmed: 30633172
Sao Paulo Med J. 2000 Sep 7;118(5):125-30
pubmed: 11018845
Curr Opin Oncol. 2007 Sep;19(5):446-51
pubmed: 17762569
Curr Opin Oncol. 2010 Sep;22(5):437-42
pubmed: 20639761
J Natl Cancer Inst. 2009 Nov 4;101(21):1510-22
pubmed: 19776382
Int J Cancer. 2008 Jun 1;122(11):2590-3
pubmed: 18224690
AIDS Patient Care STDS. 2019 Nov;33(11):459-465
pubmed: 31682165
Br J Ophthalmol. 1997 Jul;81(7):595-8
pubmed: 9290377
Br J Ophthalmol. 2012 Dec;96(12):1517-21
pubmed: 22942158
Arch Pathol Lab Med. 2009 Aug;133(8):1246-50
pubmed: 19653719
Acta Ophthalmol. 2021 Aug;99(5):478-488
pubmed: 33191633
Cornea. 2018 Oct;37(10):1292-1298
pubmed: 29985794
S Afr Med J. 2015 Apr 07;105(5):379-83
pubmed: 26242668
Invest Ophthalmol Vis Sci. 2013 Dec 11;54(13):8069-78
pubmed: 24255045
J Cancer. 2020 Jan 17;11(7):1737-1750
pubmed: 32194785
Br J Ophthalmol. 1997 Apr;81(4):308-13
pubmed: 9215061
Cornea. 2021 Aug 1;40(8):1002-1006
pubmed: 33201056
Cornea. 2000 Mar;19(2):159-62
pubmed: 10746446
Int J Cancer. 2010 Jul 15;127(2):427-32
pubmed: 19908234
Health Sci Rep. 2019 Jan 10;2(2):e108
pubmed: 30809594
J Clin Microbiol. 1999 Sep;37(9):2852-7
pubmed: 10449464
Am J Ophthalmol. 1990 Jul 15;110(1):23-7
pubmed: 2164326
Viruses. 2020 Jul 16;12(7):
pubmed: 32708700
Br J Cancer. 2013 Oct 1;109(7):1981-8
pubmed: 24030075
Br J Ophthalmol. 2002 Feb;86(2):168-73
pubmed: 11815342
Curr Eye Res. 2009 Aug;34(8):666-71
pubmed: 19899994
Appl Environ Microbiol. 2003 Dec;69(12):7377-84
pubmed: 14660388
Br J Cancer. 2010 Jan 19;102(2):262-7
pubmed: 19997105
Br J Cancer. 2004 May 4;90(9):1777-9
pubmed: 15150602
Adv Exp Med Biol. 2017;1018:167-179
pubmed: 29052137
East Afr Med J. 2006 May;83(5):267-70
pubmed: 16866221
Arch Ophthalmol. 2009 Jan;127(1):31-2
pubmed: 19139334
Int J Cancer. 2017 Aug 15;141(4):664-670
pubmed: 28369882
AIDS. 2015 Oct 23;29(16):2173-81
pubmed: 26182198
BMC Health Serv Res. 2017 Jul 14;17(1):485
pubmed: 28705204
J Clin Microbiol. 2008 Apr;46(4):1161-8
pubmed: 18234872
Front Oncol. 2018 Jun 13;8:211
pubmed: 29951372
Invest Ophthalmol Vis Sci. 2019 May 1;60(6):2388-2398
pubmed: 31141610
Br J Ophthalmol. 2006 Jul;90(7):894-9
pubmed: 16540490
Am J Clin Pathol. 2002 Mar;117(3):429-36
pubmed: 11888082
Mutagenesis. 2004 Sep;19(5):399-401
pubmed: 15388813
Eur J Cancer Prev. 2013 Nov;22(6):566-8
pubmed: 23752127
Arch Ophthalmol. 1986 Dec;104(12):1801-5
pubmed: 3024607
Adv Anat Pathol. 2006 Jan;13(1):8-15
pubmed: 16462152
AIDS. 2016 Jan;30(2):273-91
pubmed: 26691548
Viruses. 2020 Feb 26;12(3):
pubmed: 32111001
Ocul Oncol Pathol. 2021 Mar;7(2):108-120
pubmed: 33869164
Indian J Ophthalmol. 2007 Sep-Oct;55(5):361-3
pubmed: 17699945
Adv Pharmacol. 2008;56:509-57
pubmed: 18086422
Infect Agent Cancer. 2008 Sep 10;3:12
pubmed: 18783604
Infect Agent Cancer. 2011 Nov 18;6:24
pubmed: 22099431
Cancer Res. 2003 May 1;63(9):2338-43
pubmed: 12727860
Mod Pathol. 2020 Jan;33(1):74-90
pubmed: 31485010
Eye Contact Lens. 2018 Sep;44 Suppl 1:S312-S315
pubmed: 27058828
J Clin Pathol. 2007 Dec;60(12):1365-72
pubmed: 18042692
N Engl J Med. 1989 Jun 1;320(22):1442-6
pubmed: 2541337
Int J Cancer. 2020 Nov 15;147(10):2862-2870
pubmed: 32525572
Arch Ophthalmol. 1999 Dec;117(12):1593-9
pubmed: 10604662
Ocul Surf. 2013 Jul;11(3):193-205
pubmed: 23838020
Curr HIV/AIDS Rep. 2008 Aug;5(3):120-5
pubmed: 18627660
Eye (Lond). 2014 Aug;28(8):962-7
pubmed: 24858526
Theranostics. 2018 Oct 22;8(19):5307-5319
pubmed: 30555548
J Transl Med. 2018 Mar 21;16(1):77
pubmed: 29562930
Aust N Z J Ophthalmol. 1997 Aug;25(3):211-5
pubmed: 9296295
Br J Ophthalmol. 2003 Apr;87(4):396-8
pubmed: 12642297
Ophthalmic Plast Reconstr Surg. 2000 Nov;16(6):443-9
pubmed: 11106189
Virchows Arch. 2006 Mar;448(3):301-5
pubmed: 16328355
J Clin Microbiol. 2000 Nov;38(11):4114-20
pubmed: 11060077
Open Ophthalmol J. 2008 Mar 28;2:48-56
pubmed: 19516893
Oncotarget. 2017 Jan 24;8(4):7175-7180
pubmed: 27764780
Trop Med Int Health. 2013 Dec;18(12):1424-43
pubmed: 24237784
Int Ophthalmol. 2021 Nov;41(11):3599-3605
pubmed: 34173153
Ophthalmology. 2002 Mar;109(3):542-7
pubmed: 11874759
J Med Virol. 2019 Feb;91(2):308-316
pubmed: 30281790
Br J Ophthalmol. 2021 Jun;105(6):878-883
pubmed: 31649051
Lancet. 1995 Mar 18;345(8951):695-6
pubmed: 7885126
Am J Clin Pathol. 2004 Dec;122(6):938-43
pubmed: 15539387
Invest Ophthalmol Vis Sci. 1992 Jan;33(1):184-9
pubmed: 1309728
Am J Surg Pathol. 2016 Apr;40(4):519-28
pubmed: 26735858